Minoo Ahmadinejad Explores Emicizumab
Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:
”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.
Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.
Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.
The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.
Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”
Stay updated with Hemostasis Today.
-
May 13, 2026, 07:35Ifeanyichukwu Ifechidere: Why DIC is the Condition That Humbles even the Most Experienced Scientists
-
May 13, 2026, 07:26Genoveva Uzunova: Why It’s Time to Close the Sex Variable Gap in Healthcare
-
May 13, 2026, 07:09Auston Cherbonneaux: Why Erythritol Just Joined the High-Hazard List
-
May 13, 2026, 06:48Akshat Jain: Transforming Sickle Cell Care With Practical Apheresis Frameworks
-
May 13, 2026, 06:35Dima Shulkin: How Neutrophil Extracellular Traps Shape ACS
-
May 13, 2026, 05:50Danny Hsu: Global Maternal VTE Awareness and Opportunities for Prevention
-
May 13, 2026, 05:50Ney Carter Borges: Clinical Cardiovascular Polygenic Risk Report for 8 Conditions
-
May 13, 2026, 05:49Kalyan Roy: A New Blood Group System Has Been Discovered
-
May 13, 2026, 05:07Azin Alizadehasl: Unraveling DIC in Cancer-Driven Coagulopathy